NovaBridge Biosciences (NBP) stock
NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 0/30
$0.90+0.08 (+9.83%)
Close on Nov 18, 2026Market cap $104.20MP/E –Yield –
NovaBridge Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
NovaBridge Biosciences's R&D Expenses for the twelve months ending Dec 31, 2020 was CN¥984.69M, up 17.2% year over year. For fiscal 2023 it was CN¥810.65M, down 10.4% from the year before. The highest annual figure on record is CN¥1.21B in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | CN¥810.65M | -10.4% |
| FY2022 | Dec 31, 2022 | CN¥904.90M | -25.4% |
| FY2021 | Dec 31, 2021 | CN¥1.21B | +23.2% |
| FY2020 | Dec 31, 2020 | CN¥984.69M | +17.2% |
| FY2019 | Dec 31, 2019 | CN¥840.42M | +97.3% |
| FY2018 | Dec 31, 2018 | CN¥426.03M | +59.5% |
| FY2017 | Dec 31, 2017 | CN¥267.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | CN¥286.23M | – |
| Q4 FY2019 | Dec 31, 2019 | CN¥262.04M | – |
See a number that looks wrong?